1
|
Peterson NV, Kendal J, Savjani RR, Wessel L, Deng J, Crompton J, Bernthal NM, Eilber FC, Reddy VK, Kalbasi A. Surgical Outcomes in Patients Treated with 5-Day Preoperative Radiotherapy for Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys 2023; 117:e333. [PMID: 37785173 DOI: 10.1016/j.ijrobp.2023.06.2386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Treatment for high-risk soft tissue sarcoma (STS) of the extremity/trunk includes radiation therapy (RT) and surgical resection. Initial results of a phase 2 single arm trial of 5-day preoperative RT demonstrated acceptable safety and local control. Here we report an update of detailed surgical outcomes among patients treated with 5-day preoperative RT alone on the original phase 2 study, as well as an ongoing expansion cohort. MATERIALS/METHODS We conducted an updated analysis of surgical complications from a previously reported phase 2 trial of 50 patients with high-risk extremity/trunk STS treated with 5-day preoperative RT (30 Gy over 5 consecutive daily fractions) and surgery. The current analysis includes additional patients from an ongoing IRB-approved expansion cohort of the phase 2 study, which was designed to compare wound complication rates between patients receiving neoadjuvant chemotherapy and those receiving RT alone. However, given that the primary endpoint of this study has not matured, here we present only the data for patients treated with 5-day preoperative RT alone (n = 44; data cutoff date: February 17, 2022). We generated a secure prospective patient database and extracted data including demographic variables, cancer characteristics and surgical outcomes. Minimum post-operative follow-up was 90 days. Statistical analysis was performed using R (v4.2). RESULTS From a total of 94 patients, mean age was 57 (17-90), 40 (42.5%) were female, 10 (10.6%) were diabetic and 8 patients (8.5%) were active smokers or had a >10 pack-year smoking history. Median follow up was 24 months (IQR 10.6-41.8). The most common histologic diagnosis was undifferentiated pleomorphic sarcoma (n = 38, 40.4%). The most common location was the lower extremity (n = 57, 60.6%). Overall, 26 (27.7%) patients experienced surgical wound complications. In the lower extremity, wound complications occurred in 18 patients (31.6%). In all other sites, wound complications occurred in 8 patients (21.6%) (p = 0.41). Twenty-seven (28.7%) cases required local tissue advancement for primary closure and 12 of these patients (44.4%) experienced a wound complication (p = 0.04). Wound dehiscence occurred in 18 patients at a median duration of 43.5 days (IQR 40.3-85.3) from surgery, comprising 69.2% of all wound complications. Secondary surgical intervention was required in 28 patients (29.8%), of which 7 were oncologic re-excisions and 15 were irrigation and debridement. On multivariate analysis, the use of advancement flaps (OR = 5.39; p = 0.004) and diabetes (OR = 4.08; p = 0.07) were associated with wound complications. CONCLUSION Five-day preoperative RT for STS results in rates of wound complications comparable to standard fractionation. We identified local advancement flaps as the primary factor associated with wound complications. STS of the lower extremity that require complex closure warrant close attention for dehiscence.
Collapse
Affiliation(s)
- N V Peterson
- Department of Radiation Oncology, University of California Irvine, Irvine, CA
| | - J Kendal
- Department of Orthopedic Surgery, University of California Los Angeles, Santa Monica, CA
| | - R R Savjani
- Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
| | - L Wessel
- Department of Orthopedic Surgery, University of California Los Angeles, Santa Monica, CA
| | - J Deng
- Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA
| | - J Crompton
- Department of Surgical Oncology, University of California Los Angeles, Los Angeles, CA
| | - N M Bernthal
- Department of Orthopedic Surgery, University of California Los Angeles, Santa Monica, CA
| | - F C Eilber
- Department of Surgical Oncology, University of California Los Angeles, Los Angeles, CA
| | - V K Reddy
- Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA
| | - A Kalbasi
- Department of Radiation Oncology, Stanford Cancer Institute, Stanford School of Medicine, Palo Alto, CA
| |
Collapse
|
2
|
Tap WD, Eilber FR, Rosen G, Eckardt J, Schwartz A, Federman N, Eilber FC. Long-term follow-up (>20 years) for one of the original randomized prospective trials evaluating adjuvant chemotherapy in patients with high-grade operable osteosarcoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10514] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10514 Background: Neoadjuvant and adjuvant chemotherapy is now standard practice for patients who present with localized osteosarcoma. We present the long-term follow-up (>20years) for one of the original prospective randomized trials that compared adjuvant chemotherapy to no treatment in patients with high-grade operable osteosarcoma. Methods: The original study was performed at UCLA from 1981 to 1984. During this time, 59 patients with high-grade, operable, non-metastatic osteosarcoma were randomized to receive adjuvant chemotherapy (MSKCC T-10B protocol)(N=32; 24 men, 8 women, median age 15 yrs) vs. expectant management (N=27; 20 men, 7 women, median age 18 yrs). All patients received one neoadjuvant course of intra-arterial doxorubicin hydrochloride (90mg) and radiation (1750cGy). At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free (55% vs. 20%, p<.01) and overall survival (80% vs. 48%, p<.01) for those who received immediate adjuvant chemotherapy. Upon recurrence, patients in the T-10B arm received salvage chemotherapy with doxorubicin hydrochloride and cisplatin while those in the expectant arm received the T-10B protocol. 27 years after the initiation of the trial, long-term follow-up was obtained on all patients. Results: Median follow-up time for survivors was 24 years. 18 patients in the adjuvant chemotherapy arm died of disease (DOD) while 14 have no evidence of disease (NED). 22 patients in the control arm DOD, 1 died of other causes and 4 have NED. The 5, 10, and 20 year disease specific survival (DSS) for the treatment arm (47%, 43%, 43% respectfully) was significantly better than that of the control arm (30%, 26%, 17% respectfully) (p=0.0254). Conclusions: Early administration of chemotherapy in patients with high-grade operable osteosarcoma provides a significant survival benefit that is maintained with long-term (>20 years) follow-up. These results support the idea that early systemic treatment offers the best opportunity to cure patients with this high-risk malignancy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- W. D. Tap
- UCLA Medical Hematology Oncology, Los Angeles, CA; St. Vincent's Hospital, New York, NY
| | - F. R. Eilber
- UCLA Medical Hematology Oncology, Los Angeles, CA; St. Vincent's Hospital, New York, NY
| | - G. Rosen
- UCLA Medical Hematology Oncology, Los Angeles, CA; St. Vincent's Hospital, New York, NY
| | - J. Eckardt
- UCLA Medical Hematology Oncology, Los Angeles, CA; St. Vincent's Hospital, New York, NY
| | - A. Schwartz
- UCLA Medical Hematology Oncology, Los Angeles, CA; St. Vincent's Hospital, New York, NY
| | - N. Federman
- UCLA Medical Hematology Oncology, Los Angeles, CA; St. Vincent's Hospital, New York, NY
| | - F. C. Eilber
- UCLA Medical Hematology Oncology, Los Angeles, CA; St. Vincent's Hospital, New York, NY
| |
Collapse
|
3
|
Donahue TR, Kattan MW, Nelson SD, Tap WD, Eilber FR, Eilber FC. Impact of neoadjuvant therapy on histopathologic response and survival in patients with primary high-grade retroperitoneal soft tissue sarcomas. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Benz MR, Weber WA, Allen-Auerbach MS, Tap WD, Elashoff D, Eckardt JJ, Dry SM, Phelps ME, Czernin J, Eilber FC. Tumor FDG-uptake after the initial cycle of chemotherapy and histopathologic response to neoadjuvant therapy in high-grade soft tissue sarcomas. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Evilevitch V, Weber WA, Tap WD, Chow K, Allen-Auerbach M, Nelson SD, Eilber FR, Eckardt JJ, Czernin J, Eilber FC. Change in quantitative FDG-PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10017 Background: Change in size by RECIST (Response Evaluation Criteria in Solid Tumors) has been the standard to assess response to therapy in non-GIST soft tissue sarcomas (STS). Although recent studies have demonstrated that Positron Emission Tomography with F18-fluorodeoxyglucose (FDG-PET) may be used to assess response, there has not been a direct comparison between these modalities. The aim of this study was to prospectively evaluate whether a change in quantitative FDG-PET or a change in size [computed tomography(CT)] was more accurate at predicting histopathologic response to neoadjuvant therapy in patients with high grade STS using a combined FDG-PET/CT scan. Methods: From 1/05 - 12/06 58 patients with resectable biopsy proven high grade STS scheduled to undergo neoadjuvant chemotherapy were prospectively enrolled in this study. Patients underwent FDG-PET/CT prior to and after neoadjuvant treatment (prior to surgery). Tumor FDG-uptake was quantified by standardized uptake values (SUV). Changes in tumor size were quantified according to RECIST. Following tumor resection, response was assessed histopathologically. Patients with = 10% viable tumor cells were classified as responders. To date, 36 patients have completed the study and are the subject of this analysis. Results: In histopathologic responders (n=10, 28%), reduction of tumor FDG-uptake was significantly greater (-64%) than in histopathologic non-responders (-37%), (p=0.005). Using a 50% decrease in tumor SUV as a threshold value resulted in a sensitivity of 90% and a specificity of 58% for assessment of histopathologic response (p=0.01). Response assessment per RECIST showed no significant correlation with histopathologic response (sensitivity 20%, specificity 89%, p=0.4). There was no correlation between changes in tumor size and histopathologic response (area under the ROC curve = 0.6, p=0.1). Conclusions: In patients with high grade STS, quantitative FDG-PET was significantly more accurate than size based criteria for assessment of histopathologic response to neoadjuvant therapy. FDG-PET should be considered as a modality to monitor treatment response is patients with high grade STS. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - W. D. Tap
- UCLA School of Medicine, Los Angeles, CA
| | - K. Chow
- UCLA School of Medicine, Los Angeles, CA
| | | | | | | | | | - J. Czernin
- UCLA School of Medicine, Los Angeles, CA
| | | |
Collapse
|
6
|
Chawla SP, Sankhala KK, Chua V, Menendez LR, Eilber FC, Eckardt JJ, Daly ST, Rana GS, Bedrosian CL, Demetri GD. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9068] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. P. Chawla
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - K. K. Sankhala
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - V. Chua
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - L. R. Menendez
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - F. C. Eilber
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - J. J. Eckardt
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - S. T. Daly
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - G. S. Rana
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - C. L. Bedrosian
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| | - G. D. Demetri
- The Cancer Ctr of Midway Hosp, Los Angeles, CA; Keck Sch of Medicine of USC, Los Angeles, CA; UCLA David Geffen Sch of Medicine, Los Angeles, CA; ARIAD Pharmaceuticals, Inc, Cambridge, MA; Dana-Farber Cancer Inst, Boston, MA
| |
Collapse
|
7
|
Eilber FC, Eilber FR, Eckardt JJ, Rosen G, Forscher C, Maki RG, Grobmyer SR, Brennan MF, Singer S. Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. C. Eilber
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| | - F. R. Eilber
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| | - J. J. Eckardt
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| | - G. Rosen
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| | - C. Forscher
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| | - R. G. Maki
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| | - S. R. Grobmyer
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| | - M. F. Brennan
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| | - S. Singer
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of California Los Angeles, Los Angeles, CA
| |
Collapse
|
8
|
Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, Dorey F, Eilber FR. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19:3203-9. [PMID: 11432887 DOI: 10.1200/jco.2001.19.13.3203] [Citation(s) in RCA: 229] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
PURPOSE To determine whether treatment-induced pathologic necrosis correlates with local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas. PATIENTS AND METHODS Four hundred ninety-six patients with intermediate- to high-grade extremity soft tissue sarcomas received protocol neoadjuvant therapy. All patients underwent surgical resection after neoadjuvant therapy and had pathologic assessment of tumor necrosis in the resected specimens. RESULTS The 5- and 10-year local recurrence rates for patients with > or = 95% pathologic necrosis were significantly lower (6% and 11%, respectively) than the local recurrence rates for patients with less than 95% pathologic necrosis (17% and 23%, respectively). The 5- and 10-year survival rates for the patients with > or = 95% pathologic necrosis were significantly higher (80% and 71%, respectively) than the survival rates for the patients with less than 95% pathologic necrosis (62% and 55%, respectively). Patients with less than 95% pathologic necrosis were 2.51 times more likely to develop a local recurrence and 1.86 times more likely to die of their disease as compared with patients with > or = 95% pathologic necrosis. The percentage of patients who achieved > or /= 95% pathologic necrosis increased to 48% with the addition of ifosfamide as compared with 13% of the patients in all the other protocols combined. CONCLUSION Treatment-induced pathologic necrosis is an independent predictor of both local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas. A complete pathologic response (> or = 95% pathologic necrosis) correlated with a significantly lower rate of local recurrence and improved overall survival.
Collapse
Affiliation(s)
- F C Eilber
- Division of Surgical Oncology, University of California Los Angeles Sarcoma Research Group, University of California Los Angeles, Los Angeles, CA, USA
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Andrews KJ, Ribas A, Butterfield LH, Vollmer CM, Eilber FC, Dissette VB, Nelson SD, Shintaku P, Mekhoubad S, Nakayama T, Taniguchi M, Glaspy JA, McBride WH, Economou JS. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Cancer Res 2000; 60:6457-64. [PMID: 11103813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
The cytokine interleukin-12 (IL-12) has shown potent antitumor activity in several tumor models. Recently, natural killer (NK) T cells have been proposed to mediate the antitumor effects of IL-12. In this study, the antitumor response of IL-12 was investigated in a gene therapeutic model against s.c. growing mouse hepatocellular carcinomas using an adenoviral vector expressing murine IL-12 (AdVmIL-12). An adenoviral-based system was chosen because of the ability of adenoviruses to transduce dividing and nondividing cells and because of their high transduction efficiencies. Our goals were to examine the efficacy of AdVmIL-12 in a hepatocellular carcinoma model and to investigate the mechanism of the AdVmIL-12-mediated antitumor response with specific interest in the role of NK T cells. Our studies demonstrate that intratumoral AdVmIL-12-mediated regression of s.c. hepatocellular tumors is associated with rapid antitumor responses. AdVmIL-12 treatment was associated with an immune cellular infiltrate consisting of CD4 and CD8 T lymphocytes, macrophages, NK cells, and NK T cells. Antibody ablation of CD4 and CD8 T cells and use of NK cell-defective beige mice failed to abrogate the response to AdVmIL-12. Studies in T-cell- and B-cell-deficient severe combined immunodeficient and recombinase activating gene-2-deficient mice and T-cell-, B-cell-, and NK cell-defective severe combined immunodeficient/beige mice also failed to abrogate this response. AdVmIL-12 retained potent antitumor activity in mice with specific genetic defects in immune cellular cytotoxicity (perforin knockout mice) and costimulation (CD28 knockout mice). Use of mice with specific NK T cell deficiencies, Valpha14 T-cell receptor and CD1 knockout mice, also failed to abrogate the response to AdVmIL-12. Histological and immunohistochemical studies of AdVmIL-12-treated tumors showed extensive inhibition of neovascularization and a marked decrease in factor VIII-stained endothelial cells. Our studies indicate that the antitumor response of AdVmIL-12 is independent of direct cytotoxic cellular immunity (specifically, the function of NK T cells) and suggest that the initial mechanisms of AdVmIL-12-mediated tumor regression involve inhibition of angiogenesis.
Collapse
MESH Headings
- Adenoviridae/genetics
- Adenoviridae/immunology
- Animals
- Antigens, CD1/immunology
- CD28 Antigens/immunology
- Cytotoxicity, Immunologic
- Disease Models, Animal
- Humans
- Immunocompromised Host/immunology
- Interleukin-12/genetics
- Interleukin-12/immunology
- Killer Cells, Natural/immunology
- Liver Neoplasms, Experimental/immunology
- Liver Neoplasms, Experimental/therapy
- Membrane Glycoproteins/immunology
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, SCID
- Neovascularization, Pathologic/prevention & control
- Perforin
- Pore Forming Cytotoxic Proteins
- T-Lymphocytes/immunology
Collapse
Affiliation(s)
- K J Andrews
- Division of Surgical Oncology, University of California Los Angeles, 90095, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Gastrointestinal stromal sarcomas, formerly categorized as leiomyosarcomas of gastrointestinal origin, have a common pattern of intraperitoneal dissemination. Despite surgical resection with or without adjuvant systemic chemotherapy the vast majority of these patients succumb to intraperitoneal sarcomatosis and/or hepatic metastases. In an attempt to improve upon the morbidity and mortality associated with this disease we and several other centers have begun treating these patients with intraperitoneal chemotherapy. We have found that aggressive surgical resection with postoperative intraperitoneal chemotherapy has significantly lowered the peritoneal recurrence rate in patients with recurrent gastrointestinal stromal sarcomas as compared to those who have undergone surgical resection alone. However, this treatment approach has proven to be ineffective in preventing hepatic metastases, and thus has had little effect upon overall survival. With the treatment of primary rather than recurrent disease we hope to interrupt the disease process at an earlier stage further decreasing peritoneal recurrences and potentially improving survival.
Collapse
Affiliation(s)
- F C Eilber
- Division of Surgical Oncology, 54-140 CHS, UCLA Medical Center, Los Angeles, CA 90095-1782, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Abstract
The approach to the management of retroperitoneal tumors begins with a complete history and physical examination. Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis. Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy. If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI). The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning. Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases. Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner. Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor. Frequently this includes adjacent organs such as colon, small bowel, kidney, adrenal, and pancreas. Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit. Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection. Follow-up CT scans at 6-month intervals and surgical resection of recurrences can be valuable.
Collapse
Affiliation(s)
- F C Eilber
- Department of Surgery, Division of Surgical Oncology, 54-140 CHS, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA, 90095-1782, USA
| | | | | |
Collapse
|
12
|
Abstract
Limb salvage is now possible for the majority of patients with extremity sarcomas. Although overall prognosis is primarily based on tumor size and histologic grade, complete surgical excision and local control is essential for cure. There are, however, certain anatomic locations such as the flexor fossae in which a complete surgical margin is difficult to attain, and surgery without adjuvant therapy has a high local failure and amputation rate. We have found that preoperative adjuvant therapy consisting of chemotherapy and radiation followed by surgical excision with tumor-free margins has been successful in treating flexor fossa sarcomas with high limb salvage (96%), local control (89%) and overall survival rates (70%). These results are comparable to patients with similar large, high-grade extremity tumors in other compartmental locations.
Collapse
Affiliation(s)
- F C Eilber
- Division of Surgical Oncology, University of California, Los Angeles, 90095, USA
| | | | | | | | | | | |
Collapse
|
13
|
Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999; 6:645-50. [PMID: 10560849 DOI: 10.1007/s10434-999-0645-8] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
BACKGROUND Recurrent abdominal sarcomas have an extremely high rate of recurrence and poor overall survival. A prospective study was initiated to assess the feasibility, toxicity, and benefit of surgical resection and intraperitoneal chemotherapy for improving local control of disease and overall survival. METHODS Fifty-four patients underwent surgical excision of all gross disease and postoperative intraperitoneal chemotherapy with mitoxantrone. Thirty-five patients had peritoneal disease only (stage II), and 19 patients had peritoneal disease with hepatic metastases (stage III). RESULTS Nine (17%) patients remain free of disease with a mean follow-up of 37 months. The remaining 45 patients (83%) have had recurrence, with a mean interval to recurrence of 11 months. Stage (P = .001) and grade (P = .005) were the only two variables found to significantly affect recurrence. There was an overall peritoneal recurrence rate of 48% and an overall hepatic failure rate of 69%. Nineteen (35%) of the patients are alive, with a mean follow-up of 46 months. The overall 5-year survival was 31%. The 5-year survival for stage II patients was 46%; for stage III patients, it was only 5%. Stage (P = .001) and grade (P = .056) were the only two variables found to significantly affect survival. There were no treatment-related deaths, and only 5 patients (9%) developed local complications. CONCLUSIONS Aggressive surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas is a feasible treatment approach with minimal toxicity. Although this treatment had little effect on the hepatic spread of this disease and thus overall survival, it appears to have significantly lowered the rate of peritoneal recurrence and may provide a survival benefit for patients with disease limited to the peritoneum.
Collapse
Affiliation(s)
- F C Eilber
- Division of Surgical Oncology, UCLA Musculo-Skeletal Study Group, University of California, Los Angeles 90095, USA
| | | | | | | | | | | |
Collapse
|
14
|
Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Economou JS. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 1999; 59:4369-74. [PMID: 10485485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
An E1B gene-attenuated adenovirus (dl1520) has been proposed to have a selective cytolytic activity in cancer cells with a mutation or deletion in the p53 tumor suppressor gene (p53-null), a defect present in almost half of human hepatocellular carcinomas (HCCs). In this study, the in vitro and in vivo antitumor activity of dl1520 was investigated focusing on two human HCC cell lines, a p53-wild type (p53-wt) cell line and a p53-null cell line. dl1520 was tested for in vitro cytopathic effects and viral replication in the human HCC cell lines Hep3B (p53-null) and HepG2 (p53-wt). The in vivo antitumor effects of dl1520 were investigated in tumors grown s.c. in a severe combined immunodeficient mouse model. In addition, the combination of dl1520 infection with systemic chemotherapy was assessed in these tumor xenografts. At low multiplicities of infection, dl1520 had an apparent p53-dependent in vitro viral growth in HCC cell lines. At higher multiplicities of infection, dl1520 viral replication was independent of the p53 status of the target cells. In vivo, dl1520 significantly retarded the growth of the p53-null Hep3B xenografts, an effect augmented by the addition of cisplatin. However, complete tumor regressions were rare, and most tumors eventually grew progressively. dl1520 had no effect on the in vivo growth of the p53-wt HepG2 cells, with or without cisplatin treatment. The E1B-deleted adenoviral vector dl1520 has an apparent p53-dependent effect in HCC cell lines. However, this effect is lost at higher viral doses and only induces partial tumor regressions without tumor cures in a human HCC xenograft model.
Collapse
Affiliation(s)
- C M Vollmer
- Division of Surgical Oncology, University of California Los Angeles, 90095-1782, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Vollmer CM, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999; 59:3064-7. [PMID: 10397245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
The majority of human hepatocellular carcinomas overexpress alpha-fetoprotein (AFP). Two genetic immunization strategies were used to determine whether AFP could serve as a target for T-cell immune responses. Dendritic cells engineered to express AFP produced potent T-cell responses in mice, as evidenced by the generation of AFP-specific CTLs, cytokine-producing T cells, and protective immunity. AFP plasmid-based immunization generated less potent responses. These novel observations demonstrate that this oncofetal antigen can serve as an effective tumor rejection antigen. This provides a rational, gene therapy-based strategy for this disease, which is responsible for the largest number of cancer-related deaths worldwide.
Collapse
Affiliation(s)
- C M Vollmer
- Division of Surgical Oncology, University of California Los Angeles, 90095-1782, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|